Drugs / ORTHO EVRA
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ORTHO EVRA | — | 2001-11-20 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00125983 | ? → Jan 2007 | HIV infectious disease, pregnancy disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00357981 | — | dysmenorrhea | University of California, San Francisco | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORTHO EVRA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00357981 ↗ |
| Route | Other | “Because Ortho Evra is administered as a contraceptive patch worn on the skin, it may bypass the metabolic pathway common to both PIs and oral contraceptives” NCT00125983 ↗ |